Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Science 11 August 2000:
Vol. 289. no. 5481, p. 833
DOI: 10.1126/science.289.5481.833d

Editors' Choice: Highlights of the recent literature

Prolyl isomerases are most familiar as the targets of the immunosuppressive drugs cyclosporin and FK506, which bind, respectively, to cyclophilins and FK506-binding proteins (FKBPs). An as yet intractable puzzle has been the cellular function of these enzymes, which generally are not essential for viability.

Wu et al. have studied a third class of prolyl isomerases, typified by Ess1 which is essential for growth in yeast. Unlike the other two kinds, Ess1 contains a WW domain (so-called for two invariant tryptophans) in addition to the catalytic domain; the WW domain is known to interact with phosphoserine-proline sequences. From a combination of genetic (to identify suppressors) and biochemical (to characterize interactions) experiments, they conclude that Ess1 functions by binding to the C-terminal domain (CTD) of RNA polymerase. Thus, Ess1 would control the recruitment of transcriptional regulatory factors via their interactions with the CTD--which is known to include many copies of a seven-residue repeat containing two serine-proline motifs.

Arévalo-Rodríguez et al. have examined the interactions of cyclophilin and Ess1 with components of a chromatin remodeling complex, while Verdecia et al. describe the structure of a WW domain bound to the doubly phosphorylated heptad repeat. -- GJC

EMBO J. 19, 3727 (2000); EMBO J. 19, 3739 (2000); Nature Struct. Biol. 7, 639 (2000).





To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)